Hi Dr T,
Congratulations on your appointment to CEO, good to see you back in the driver’s seat.
Are you referring to the ability of VO2Peak (compared to LVEF - left ventricle ejection fraction) to more accurately measure the negative effect of cardiotoxicity and therefore prove/quantify the cardio protect benefit of bisantrene? Or is there some other advantage that I am missing?
If it's just a better measure of heart health, why is this a bigger advantage than opening up the trial to many more cancer indications which I would have thought would increase significantly the TAM?
I didn’t see today’s presentation, waiting for the recorded video to be released.
Hi Dr T, Congratulations on your appointment to CEO, good to see...
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |